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Abstract: Stabilin-2/HARE is the primary clearance receptor for circulating hyaluronan (HA), a
polysaccharide found in the extracellular matrix (ECM) of metazoans. HA has many biological
functions including joint lubrication, ocular turgor pressure, skin elasticity and hydration, cell
motility, and intercellular signaling, among many others. The regulatory system for HA content in
the tissues, lymphatics, and circulatory systems is due, in part, to Stabilin-2/HARE. The activity of
this receptor was discovered about 40 years ago (early 1980s), cloned in the mid-1990s, and has been
characterized since then. Here, we discuss the overall domain organization of this receptor and how
it correlates to ligand binding, cellular signaling, and its role in known physiological disorders such
as cancer.
Keywords: Stabilin-2; hyaluronan; HARE; MAPK; signaling; receptor; ligand; clearance

1. Introduction
The focus of this review is the interactions of hyaluronan (HA) with Stabilin-2 in both
physiologically normal and diseased states. HA is a long unmodified polysaccharide containing
alternating sugars consisting of glucuronic acid and N-acetylglucosamine. Stabilin-2 is one of two
members of the scavenger receptor class H family and is the only one that binds HA. Although fiftyfive percent of the amino acids that compose Stabilin-1 are homologous to those of Stabilin-2, it does
not bind HA, and thus Stabilin-1 will not be reviewed in this manuscript. The biological activity of
Stabilin-2 was first discovered by Fraser et al. in experiments in which they were calculating the
clearance of HA in the blood of rabbits in the early 1980s [1,2]. Radioactive HA that is injected directly
into an ear vein is sequestered in the liver. By 1983-4, there was good evidence that the sinusoidal
endothelial cells of the liver contained a mechanism to specifically internalize HA [3,4]. The protein
receptor was first purified from sinusoidal endothelial cell (SEC) membranes and antibodies were
raised against an enriched HA-binding protein in 1997 by Yannariello-Brown et al. [5] followed by
McCourt and coworkers in 1999 [6]. A partial protein sequence was identified and then cloned in rats.
The novel receptor was named the hyaluronic acid receptor for endocytosis, or HARE [7]. Human
HARE refers to the smaller 175-kDA isoform of a larger 300-kDa full-length receptor, which was
entirely sequenced in 2002 [8]. At this time, it was named Stabilin-2, since the larger isoform had high
homology and organization similar to Stabilin-1/MS-1. Around the same time in 2002, Stabilins also
carried the name FEEL-1/FEEL-2, given that the proteins contained Fasciclin, epidermal growth
factor-like (EGF), laminin-type EGF-like, and Link domains [9]. Since FEEL was a temporary name,
it remains seldomly used to this day and Stabilin remains the widely accepted nomenclature of these
receptors. The smaller isoform of Stabilin-2 is a proteolytically processed product of the larger
isoform and has been independently characterized [10,11] (Figure 1). In this review, the smaller
isoform is referred to as “HARE” and the larger isoform is Stabilin-2. To date, all of the biological
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functions of HARE and Stabilin-2 are identical, and both are expressed in tissues and recombinant
cell lines.
2. Characteristics of Stabilin-2/HARE
As of this year (2020), there are 20 known ligands of Stabilin-2 and, despite this diversity, the
protein receptor remains a mundane sequence of EGF and fasciclin domains. Stabilin-2 is composed
of 2551 amino acids, of which 2458 are part of the extracellular domain, 21 are the single
transmembrane domain, and the remaining 72 amino acids are the intracellular domain. There are 21
epidermal growth factor (EGF) and EGF-like domains in four clusters containing five to six domains
per cluster (Figure 1). Each EGF domain has a specific folding pattern in which disulfide bonds form
between the first and third, second and fourth, and fifth and sixth cysteines within that cluster [12].
However, the “defined” domain often has more than six cysteine residues within it. In between each
EGF cluster, there are two fasciclin (Fas-1) domains often containing no cysteines. Only the fifth and
sixth Fas1 domains contain a few cysteines. The seventh Fas1 domain is adjacent to the
transmembrane domain and is the only one with a known structural organization [13]. Between the
last EGF cluster and the seven Fas1 domain is the 93-amino acid Link domain, the known HA-binding
domain, containing two disulfide bonds. Stabilin-2 contains 202 cysteines, of which 130 are known to
be paired with each other in the EGF and Link domains. The oxidation fate of the remaining 72
cysteine residues is currently unknown. The following is what we know of the individual domains
of Stabilin-2.

Figure 1. Domain organization of Stabilin-2 and the shorter isoform, hyaluronic acid receptor for
endocytosis (HARE).





Fas1: Recombinant cells that express high levels of Stabilin-2 often become sticky in that they
stick to each other. Park et al. investigated how this occurred and found that Fas1 domains
are responsible for homophilic cell–cell adhesion which also required a divalent cation such
as Mn2+, Mg2+ or Ca2+ [14]. Fas1 domains also interact with integrins in a heterophilic fashion.
Using mouse recombinant L-cells expressing Stabilin-2 and following up with human SECs,
they found that the Fas1 domains of Stabilin-2 adhere with M2 integrins on the surface of
leukocytes and that this adherence was firm and not associated with rolling nor
transmigration [15]. Further studies by the same laboratory showed that aged or apoptotic
cells such as erythrocytes are immobilized by Stabilin-2 through the interaction of V5
integrins and that engulfment occurs via the GULP adaptor-mediated activation of Rac1.
These experiments were also performed in L-cells stably expressing Stabilin-2 in which
phagocytosis could occur [16]. Since SECs do not employ phagocytic mechanisms, SECs may
immobilize the target cells in the sinusoid allowing Kupffer cells to engulf them.
Alternatively, immune cells expressing Stabilin-2 may phagocytose dead or apoptotic cells.
EGF: The inner leaflet of the plasma membrane of erythrocytes is enriched in
phosphatidylserine (PS), which flips to the outer leaflet when the cells die [17]. The exposure
of PS is a signal for phagocytic cells to “eat” the dead cell and clear it from circulation. Park
et al. discovered that the EGF domains of Stabilin-2 (and Stabilin-1) recognize PS as a binding
ligand and may immobilize apoptotic/aged cells in the sinusoids for engulfment by Kupffer
cells [18,19]. The interaction required Ca2+ and occurred at pH 7.3, but was optimal at pH 6.8.
Furthermore, the intriguing part of this story is that the second EGF domain in each cluster
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is more atypical than the other EGF domains and there is a conserved histidine which aligns
with position 1403 of the third cluster. This histidine is conserved within each EGF cluster
and between both Stabilin receptors. Mutagenesis of the histidine did not affect binding
affinity for PS, but did affect binding enhancement at lower pH, suggesting that the histidine
is protonated at lower pH (pKa ~6.0) and that other residues in the binding loop are involved
with PS interaction [20].
 Link: The Link domain is the HA binding domain for Stabilin-2. It is located between the last
EGF and Fas1 domains near the transmembrane region. Deletion of the Link domain results
in complete ablation of HA binding [21,22]. The Link domain of Stabilin-2 has highest
homology to the Link domain of tumor necrosis factor-stimulated gene-6 (TSG-6). In silico
modeling suggests that the tyrosine residues are critical for HA binding [23]. Unlike the
Stabilin-2 Link, the TSG-6 Link also binds heparin at a distal site within the domain [24].
Stabilin-2 also binds heparin, but not within the link domain and the precise location is
unknown at this time [25]. Although HA binds the Stabilin-2 Link domain with high affinity
approaching 20 nM, the interaction is relatively weak compared to other hyalectins. With the
use of atomic force microscopy for direct measurement of the interaction of the protein with
a low megaDalton polymer, HA bound to Stabilin-2 with 25 picoNewtons (pN) in
comparison to TSG-6 (24 pN), CD44 (34 pN), versican (37 pN) and aggrecan (>52 pN) [26].
Having both high affinity and the ability to release the cargo once in the early endosomes is
critical for this receptor, in contrast to the other hyalectins which only bind and form stable
matrices.
As alluded to previously, HARE is a proteolytically processed form of Stabilin-2 in which the Nterminal 1135 amino acids are cleaved from the remaining 1416 amino acid receptor bound to the
membrane at serine 1136. Recombinant cells expressing only HARE show great ligand binding and
endocytic activity. Recombinant cells expressing the full-length Stabilin-2 cDNA express both
Stabilin-2 and HARE in which the ratio of the two receptors is about 8-10:1 [10]. Expression of HARE
is much more robust in the tissues of rodents (ratio ~2:1) and, presumably, humans, than in
recombinant cell lines which may not fully express the proteolytic enzymes required for this
processing event [27]. From 35S pulse-chase experiments, we know that HARE expression in Stabilin2 expressing cells begins after the receptor is fully glycosylated; therefore, we have speculated that
the cleavage event occurs somewhere between the trans-Golgi network and the cell surface [28]. We
have used standard molecular biological techniques to delete the transmembrane and cytoplasmic
domains from Stabilin-2 to produce a soluble “ecto-domain” [10]. Cells secreting the 300-kDa ectodomain do not produce a soluble HARE, therefore, protein cleavage is dependent on membrane
anchorage [29]. Secreted ecto-domains have proven quite useful to interrogate and calculate affinities
for ligand binding using biochemical methods [10,22,30]. The ecto-domains are easily purified by
affinity and metal chelate chromatography from cell culture media and they are quite stable under
standard conditions [22]. Reducing the protein renders the protein unable to bind to any ligand, and
therefore the secondary and tertiary structures of the receptor are vitally important for its activity.
3. Ligand Binding of the LINK Domain
The 93 amino acid Link domain of Stabilin-2 is 65% homologous and 46% identical with the Link
domain of Stabilin-1. The cysteine residues are perfectly aligned, but the Stabilin-1 Link lacks the key
lysine, tyrosine and additional residues that are predicted for HA binding based on the TSG-6 model
[23,31] (Figure 2). Though it is known that Stabilin-2 binds in the low nM range for HA, there were
questions as to what other glycosaminoglycans (GAGs) are bound within the same site. The rat HARE
(rHARE) was initially cloned and expressed in SK-Hep cells in the laboratory of Prof. Paul Weigel
and the Link domain was characterized by HA binding using competition assays with other potential
ligands. Endocytosis of HA was competitive with the following chondroitin sulfates (CS) from
strongest to weakest apparent affinities; CS-E, CS-A, CSD, CS-C, CS-B (Dermatan sulfate/DS). Other
GAGs that did not bind in this assay were heparin, heparan sulfate, keratan sulfate, and non-sulfated
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chondroitin. Ligand binding was also temperature sensitive, as no ligands competed with HA at 4 °C
[32].
Similar experiments were repeated for hHARE after it was stably expressed in Flp-In 293 cells.
The chondroitin sulfate species with the highest to lowest apparent affinities in the endocytosis
competition assay were: CS-A, (CS-C, CS-D, CS-E, and non-sulfated chondroitin were all about
equal), and DS. Once again heparin, heparan sulfate, keratan sulfate did not compete. None of these
GAGs competed for HA at 4 °C. Scatchard analysis of HA binding in hHARE cells reveals that there
is a single class of non-interacting binding, suggesting that there is one receptor in these recombinant
cells that binds HA. This analysis also revealed that the affinity or Kd value is 7.2 ± 1.2 nM and that
there are about 118,000 binding sites or receptors on the cell surface [11].
With the development of using purified protein and individually labeled ligands, it was possible
to screen without competing a known ligand such as HA. This overcomes the weaknesses of the
competition assay such as 1) a weak ligand may not sufficiently compete with a strong ligand, 2)
protein conformational change for one ligand may prevent the other ligand from binding, and 3)
other non-competing binding sites will not be detected. To address this, a secreted ecto-domain of
both human Stabilin-2 isoforms (s315 for the large Stabilin-2 receptor) and sHARE (for the smaller
isoform) were created. Through a series of assays including ligand blots and an in-house
development of an ELISA-like assay, the Link domain of sHARE binds HA, which was competed
with by CS-A, CS-C, and CS-D. Both CS-E and DS bind to two sites and do compete slightly with HA
bound in the Link domain. However, heparin binding was entirely independent of HA binding. This
also confirmed that heparin does not bind within the Link domain and both ligands may bind sHARE
simultaneously. CS-E and DS also compete with heparin at the second site outside of the Link domain
[22].

Figure 2. Alignment of Link domains in TSG-6, Stab1 and Stab2.

4. Stabilin-2 As a Cellular Signaling Receptor
The cytoplasmic domain contains four Tyr, seven Ser, one His and five Thr amino acids, which
are all potentially phosphorylated (Figure 3). Using NetPhos 2.0 software to predict phosphorylation
probabilities, five candidates remain: Ser2497, Thr2523, Ser2537, Tyr2519, and Tyr2531. Of these, Tyr2519 was
confirmed to be phosphorylated through a variety of biochemical and molecular approaches and
interacts with the mitogen-activated protein kinase pathway (MAPK), specifically the extracellular
signal-regulated kinases (ERK1/2) and not JNK or p38. The Ras-Raf-MEK-ERK cascade, or MAPK
pathway, is involved with numerous cellular responses such as transcription, cell survival, migration,
cytoskeletal remodeling, differentiation, and cell cycle progression in proliferation [33]. This pathway
is often stimulated in many types of cancers and increased in roughly 1/3 of all cancers where multiple
members of the cascade may be targeted. To test if Stabilin-2/HARE may be stimulated by ligand, we
used HA due to its availability as a pure source from fermentation and because of its high affinity for
the receptor. Incubation with a small amount of polymeric HA (40 nM) stimulated HEK293 cells
stably expressing either Stabilin-2 or HARE to phosphorylate ERK1/2 which increased over a 30 min
time course and then rapidly decreased [21]. This suggests that Stabilin-2 is responsive to
extracellular clues and may signal that induction for a cellular response.
The cytoplasmic domains of both Stabilin receptors are very diverse, without any homology. As
seen in Figure 3, the cytoplasmic domain of Stabilin-2 contains four endocytic motifs; YSYFRI, FQHF,
NPLY, and DPL. Using deletion mutagenesis, the third motif, NPLY, was the most crucial for
endocytosis. Deletions of either the first or second motif also inhibited endocytosis by 50%. The fourth
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motif decreased endocytosis by less than 10%. Swapping out Tyr2519 for alanine also significantly
affected endocytosis, suggesting that receptor signaling upon ligand binding is a coordinated event
[34]. We next asked if the type of ligand influences activation of some motifs over others. As seen in
Figure 3, M1, M2, and M3 are activated by HA endocytosis, whereas, M1, M3, and M4 are activated
for heparin endocytosis [35]. Since both HA and heparin are polymers that come in a range of sizes,
HA is the most diverse with polymers containing only a few sugars to very long polymers up to 10
megaDaltons [36]. The current paradigm is that HA has multiple biological functions that are sizedependent in which smaller oligos are associated with inflammation and larger polymers tend to be
in matrices or involved with cellular quiescence [37,38]. This paradigm is being put to the test due to
sources of HA and methodology of small oligo production may introduce endotoxin in HA samples
[39]. Using the HEK293 model system, it was discovered that HA stimulates the NF-kB pathway via
the Link domain as cells expressing HARE without a Link domain were unresponsive. Using
specifically sized HA preparations to probe this interaction proved that NF-kB is dependent on a
range of 40–400 kDa HA. Polymers that were outside of this range failed to stimulate HARE-mediated
NF-kB signaling [40]. Why would this matter? There are several hypotheses to this question. First,
high molecular weight HA in the megaDalton size range is the normal mass of HA that can be found
in certain tissues in which HA is found in an extracellular matrix bound by multiple proteins. HA is
in a stable structure and there is no need for a response. Second, the 40–400 kDa size range may be
optimal for receptor dimerization in contrast to small HAs that do not allow the bulk of two large
receptors to attach efficiently or, alternatively, very large HA that does not allow the receptors to get
close enough for any synergistic activity. Lastly, HA around the 200 kDa range may be the “sweet
spot” for the transition from rod-like to coil-like HA [41]. HA in this size range signals through
Stabilin-2/HARE for a cellular response, although this receptor may internalize any HA polymer
greater than 18 sugars [40].
In an extension to the investigations of which ligands bound to HARE [22], we asked which of
these activated NF-kB, or is HA the only relevant signaling molecule for Stabilin-2/HARE? Again,
using stable cell lines, the inquiry led us to conclude that in addition to HA-mediated signaling, other
ligands including heparin, DS, and acetylated low-density lipoprotein (AcLDL) also activated NFkB. Other ligands that did not activate NF-kB were the chondroitin sulfates -A, -C, -D and -E [42]. It
is worth noting that HA and the chondroitin sulfates are the only ligands to bind within the Link
domain and with differences in their individual binding affinities. Heparin and DS bind to a distal
site and compete with each other and with AcLDL, so that within this context, we are only looking at
two binding sites on HARE: a HA/CS site which is within the Link domain and another site for
Heparin, DS, CS-E, and AcLDL. In a collaborative effort with Anne Dell of the Imperial College of
London starting in 2004, we screened the N-glycans of HARE and found a unique and large N-glycan
that modified Asp2280 which is situated in the Link domain [28]. Of the 10 sites on HARE that were
discovered to contain multiple N-glycans, only Asp2280 contained N-glycans that were sialylated.
Mutagenesis of this Asp to Ala did not affect the endocytosis of HA, but did affect binding in some
in vitro assays and we think that the absence of the glycan destabilized either the binding of HA with
the protein or slightly altered the topology of the Link domain which lowered affinity in an in vitro
experimental setting. With regard to signaling, the ablation of the glycan at position 2280 resulted in
HA binding with the receptor without activation of NF-kB. In contrast, the N2280A mutant did not
affect NF-kB signaling by heparin, DS, or AcLDL [43] suggesting that HA and the heparin cohort
bind and induce signaling through the receptor independently. Due to the signaling activities of
multiple ligands, including a size range of HA, we speculate that Stabilin-2/HARE is involved with
sensing the extracellular environment via the profile or signature of the cohort of ligands in real time.
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Figure 3. The cytoplasmic domain of Stabilin-2/HARE.

5. Physiological Functions of Stabilin-2
Stabilin-2 is expressed in the endothelium of liver [5], lymph node [27], spleen [27], bone marrow
[44] and in specialized structures of the eye, heart, and kidney [45] (Table 1). The primary function of
Stabilin-2 is dependent on the location and expression in the tissues. In the liver, it is highly expressed
in liver sinusoidal endothelial cells (LSEC) and is responsible for the systemic clearance of HA [27],
natural and infused heparin [25,46], extracellular matrix components such as chondroitin sulfates [32]
and collagen pro-peptides [47], advanced glycation end-products [48] and small phosphatidylserinebased particles [49]. Stabilin-2 was first discovered for its HA binding ability. The circulatory route
of HA catabolism, as established by T. Laurent and J.R. Fraser, is that very large megadalton-sized
HA is broken down in the tissues and drains in the lymphatic system. High expression of Stabilin-2
in lymph nodes allows for at least 80% of the HA to be eliminated at that site. The remaining HA
ends up in the blood and is taken up by LSECs, which keeps the amount of blood HA very low [50,51].
Deletion of StabilinStabilin-2 in a mouse knock-out model resulted in glomerular fibrosis which
increased in severity when Stabilin-1 was also knocked out. The cause of the kidney damage was
likely the lack of clearance of the TGF- family member growth differentiation factor 15 (GDF-15), a
ligand common for both StabilinStabilin-1 and Stabilin-2, and the accumulation of extracellular
matrix material within the glomeruli [52]. The human body must also eliminate millions of dead red
blood cells every second to achieve the turnover of all red blood cells within their lifespan of ~120
days. Stabilin-2 (and StabilinStabilin-1) may also adhere to dying and dead red blood cells and
neutrophils, which have flipped phosphatidylserine to their outer membrane, in the capillary bed of
the liver. The shear stress of circulating blood is very low in these areas of the liver and the
StabilinStabilins may immobilize these dead/dying cells for engulfment by Kupffer cells [19,53,54].
Recently, it was discovered in specialized structures of the muscle [55]. In the muscle, Stabilin-2
is involved with myoblast fusion during muscle formation and regeneration, in which it interacts
with phosphatidylserine [56]. Embryonic muscle formation or repair involves myogenic precursors
that mature to myoblasts which fuse with each other to give rise to a multi-nucleated myotube. The
myotube further matures to form skeletal muscle tissue [57]. Previous screenings of Stabilin-2
expressing tissues missed muscle since Stabilin-2 is only expressed during myogenic differentiation
through calcineurin signaling [55]. Follow-up studies investigated how this sequence of events
occurred from PS binding to cellular response. Hamoud et al. demonstrated that Stabilin-2 binding
with PS stimulated the G-protein coupled receptor (GPCR) activity of BAI3 during myoblast fusion
or in efferocytosis (phagocytosis of apoptotic bodies). BAI1-3 are adhesion GPCRs containing
thrombspondin repeats (TSRs) on the extracellular tail and an ELMO binding site on the intracellular
tail [58]. BAI3 GPCR activity was carried out through the ELMO-DOCK1-Rac1 pathway to rearrange
the cytoskeleton and complete myotube formation or completion of the efferocytosis phagosome [59].
In this process, it is likely that the extracellular Fas1 domain of Stabilin-2 interacts with the 5 integrin
domain of focal adhesion kinase and GULP, which is an adaptor protein for endocytosis and possibly
connected to the activities of Rac1 for actin rearrangement, all aiding in the stimulation and formation
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of the cupping processes of these two events [16,60,61]. In addition, extracellular signaling for
changes in transcription during myoblast fusion and myotube formation are heavily reliant on the
MAPK pathway. As alluded to previously, HA binding to Stabilin-2 induces the MAPK pathway for
inducing cellular changes and response [57]. For more information, Park and Kim have written an
excellent review delineating these processes in the journal Biomolecules [49].
Both Stabilins are expressed in bone marrow and are involved with the clearance of HA and
other extracellular matrix molecules in that localized area. Within the marrow, the endothelia is a
migration site for hematopoietic stem and progenitor cells (HSPCs) between the blood and bone [62].
Do the Stabilins have a role in cell migration in and out of the bone marrow? This question was tested
by the transfection of HEK293 cells with either Stabilin-1 or Stabilin-2 and assessing the binding of
HSPCs to these transfected cells. Stabilin-2 expressing HEK293 cells bind bone marrow cells with
higher affinity which is abrogated with the treatment of hyaluronidase [44]. Based on these
experimental data, it is highly probable that the Stabilins, particularly Stabilin-2/HARE, with its HAbinding abilities, are involved with transmigration of HSPCs between bone marrow and circulating
blood.
The human protein atlas (www.proteinatlas.org) and other similar databases using RNA
expression data show that Stabilin-2 expression is highest in the spleen. A key word search in
PubMed using “Stabilin-2 and spleen” brings up 11 references, none of which are a detailed study of
Stabilin-2 function in spleen. A similar search in the Web of Science database by Clarivate Analytics
produces similar results. What is the function of Stabilin-2 in spleen? We assume that it may be similar
to bone marrow in that there is local clearance by the extracellular matrix and other functions that are
specialized in the spleen, such as the enhanced elimination of dead blood cells, and, possibly,
elimination of bacteria [9]. We should note that a small study using human cDNA pools from the
spleen as well as from the lymph node and bone marrow identified splice variants in these tissues.
Of the nine splice variants identified, six were in the spleen and the other three were in the lymph
node and bone marrow. As the identification was based on RNA expression, it is unknown if these
variants are expressed on the protein level nor their significance to human biology [63]. A more recent
paper published in the J. of Clinical Investigations exhibits how Stabilin-2 is a clearance receptor for
von Willibrand Factor (VWF) and Factor VIII (FVIII) of the coagulation pathway [64]. Both VWF and
FVIII are naturally conjugated together in the plasma and levels of these molecules are regulated by
Stabilin-2 clearance/endocytosis activity. The rate of VWF-FVIII clearance was only modestly
decreased in a Stabilin-2 knock-out (Stab2KO) model, suggesting there are other clearance receptors
that also recognize the VWF-FVIII complex [65]. Interestingly, HA, along with unfractionated
heparin, dermatan sulfate and mannan, competed with VWF-FVIII binding to Stabilin-2 and the
presence of HA reduced the titer of FVIII-specific IgGs in a similar manner as observed in the
Stab2KO background [64]. It is thought that the mechanism for the immune response to FVIII is in
the spleen, the site of very high Stabilin-2 expression, though how Stabilin-2 affects overall titers of
FVIII-specific IgGs and immunotolerance is unknown [66]. This may very well be a case in which
levels of VWF-FVIII are regulated by Stabilin-2 in the liver and the immune component may be
regulated by Stabilin-2 in the spleen. To date, there is not one detailed study of Stabilin-2 function in
the spleen and it is an area ripe for exploration.
Table 1. Expression and Function of Stabilin-2/HARE.

Organ

Tissue

Liver

Sinusoidal endothelia

Lymph node
Spleen
Bone
marrow
Eye

Reference

Medullary sinuses
Venous sinusoids

Function
HA and other blood borne
molecule catabolism
HA catabolism
Not Determined

Venous sinusoids

Bone cell homing

[44,45]

Corneal and cuboidal
epithelium

Not Determined

[45]

[8,45,67]
[8,45,67]
[8,45,67]

Int. J. Mol. Sci. 2020, 21, 3504

Kidney

8 of 15

Renal papillae
Ependymal cells of choroid
plexuses
Mesenchymal cells of heart
valves

Not Determined

[45]

Not Determined

[45]

Not Determined

[45]

Striated
Muscle

Myocyte

Myoblast fusion in myogenesis

[55,59]

Blood

Human monocyte derived
macrophages

Clearance of cell corpse

[18]

Brain
Heart

6. Stabilin-2 and Cancer Metastasis
In 1889, Dr. Stephen Paget’s “seed and soil” theory of metastasis stated that a tumor cell (or seed)
will find a home in certain compatible tissues (soil) to continue growing in a suitable environment
[68]. Tissues with the highest expression of Stabilin-2 (sinusoids of liver, lymph node) are also the
primary targets (soil) of metastatic cancers from breast, colon, prostate, gastrointestinal, etc. (seeds)
[69]. Metastatic tumor cells often contain distinctive surface markers for enabling them to escape their
indigenous tissue to travel and thrive at a distal site. One of the common markers is CD44 and its
splice variants and this is why it has been of such interest in cancer research. CD44 is a HA binding
molecule which is not highly endocytic and many cancers (as well as immune cells) express variants
of CD44 and have abundant pericellular HA [70,71]. HA is a ubiquitous molecule and it actually helps
to “cloak” or “hide” the cancer cell from immune surveillance. Metastatic cells that are not detected
by the immune system often immobilize in the sinusoids of liver, lymph node and bone marrow. To
investigate why this occurs, Martens et al. analyzed the scavenger receptor profile of these tissues
and found a number of receptors that are pattern recognition receptors as well as specific ligand
receptors. These include both Stabilin-1 and -2, DC-SIGN, mannose receptor (MR), MARCO, and
LYVE-1 expressed by the endothelium and resident macrophages expressing MR, DC-SIGN,
Sialoadhesin, CD163, and Thrombomodulin. These receptors represent a trapping mechanism for
metastatic cells. Of these 11 receptors, only Stabilin-2 recognizes and binds with HA. It is interesting
to note that the organ with the highest expression of Stabilin-2 is the spleen, though it is not a site for
tumor metastasis. The spleen only expressed four of the 11 receptors listed here and so it may not
have the optimal profile to immobilize metastatic cells [72]. In light of the hypothesis that Stabilin-2
may aid in the retention of metastatic cells, a study focused on the remodeling of endothelium in
hepatocellular carcinoma (HCC) revealed that the loss of Stabilin-2 expression increased survival of
the patients that were sampled. As normal cells become cancerous, they de-differentiate and lose
many of their tissue-specific markers. Unfortunately, loss of Stabilin-2 expression in the peritumorous environment was the least likely to occur of all the SEC markers tested and may be a
significant factor for endothelial-tumor cell adhesion and invasion [73].
The lymphatic system or “second circulatory system” is a common transportation highway for
metastases and tumor lymphangiogenesis and is common among the various types of cancer. The
lymph node itself highly expresses Stabilin-2 and acts as one of the entrapping receptors for
metastatic tumor cells. A study in which the investigators injected PC3M-LN4 prostate cancer cells
that are known to be rich in pericellular HA in mice, found that when Stabilin-2 was blocked with a
blocking antibody prior to tumor injection, the number of lymph node metastases was dramatically
reduced [74]. A follow-up human patient study in the evaluation of tongue cancer supports this
finding in which the potential of solid tumor lymph node metastases is positively correlated with
Stabilin-2 expression in lymph node [75]. Though it is known that pericellular HA increases
metastatic potential, it also increases interaction with Stabilin-2 which allows for tumors to grow at
distal sites.
Stabilin-2 is the primary scavenger receptor for HA as mentioned previously. Mice lacking
Stabilin-2 expression (stab2KO) have very high HA levels in their circulating plasma, though the mice
are physiologically normal in all other aspects [52]. The role of circulating HA in a metastatic model
was carried out in stab2KO mice in which mice were injected with B16F10 melanoma cells and the
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number of metastatic nodules was assessed in the lungs. The results are that 1) the number of
metastatic nodules was lower in Stab2KO than WT mice, 2) there was significantly less rolling and
tethering of cells in the Stab2KO mice compared to WT, suggesting the importance of circulating HA,
or rather the lack of it, promotes metastatic cellular attachment [76]. This paper demonstrates that
Stabilin-2 does not need to directly interact with metastatic cells, but the levels of ligands also affect
metastatic activity.
CD44 and its splice variants are enriched in a variety of cancer cells and all of these receptors
bind HA [77,78]. Therefore, the use of HA as a vehicle for nanoparticles to target cancer cells may be
a promising therapeutic tool. Evaluation of HA-based nanoparticles often begin and end in the cell
culture stage without further assessment in a physiological model [79]. In the experimental animal,
nanoparticles coated with HA often accumulate in the liver due to Stabilin-2 binding and endocytosis
activities [80,81]. If HA is required for nanoparticle targeting, then it must be physically or chemically
modified to optimize delivery to the target tissue while avoiding accumulation within the liver. For
example, carboxymethylation of HA allowed for greater drug sequestration and overall efficacy of
drug delivery within a limited time window, though the study lacked some key data for liver or renal
clearance [82]. Likewise, nanoparticles coated with low molecular weight HA have higher
internalization rates by tumor cells and better efficacy than nanoparticles without HA and little to no
toxicity to either liver or kidney. However, other treatments, such as radiation, were required to
significantly hinder growth of tumors [83]. The bottom line is that many nanoparticles have been
developed for drug delivery to a variety different types of cancer and there is not yet a developed
HA-based nanoparticle that contains optimal drug delivery to the target tissue without off-target
effects while retaining the intrinsic properties of HA for binding to key receptors [84–86].
7. Conclusions and Perspectives
By definition, Stabilin-2/HARE is an excellent scavenger receptor for the following reasons: 1) it
binds and internalizes both natural and synthetic ligands, 2) it continuously recycles from the cell
surface to endosomes to accumulate exogenous cargo, and 3) the expression is relatively high in
specific cell types of tissues and organs. Moreover, the function of Stabilin-2/HARE is ever expanding
to include aspects of development. The recent discovery that Stabilin-2 is involved with myotube
development was briefly covered [55]. There are other reports that Stabilin-2 is involved with
development in which expression oscillates in the fetal liver (unpublished data) or involved with
arterial–venous differentiation in the zebrafish model [87]. What is known now is only scratching the
surface of the myriad functions for Stabilin-2 in tissue/organ development.
One of the big impediments of characterizing this receptor on the atomic level is the lack of a
known structure. Both isoforms contain an abundance of cysteine amino acids which are difficult to
fold in bacterial-based expression systems. Dr. In-San Kim’s lab used an Origami strain of E. coli to
express his constructs in Park et al. [56] and correct protein folding was estimated at 70%. More
recently, Twarda-Clapa et al. used an E. coli K12 Shuffle T7 Express Stain to express the seventh Fas1 domain for crystallization, though this is one of the few areas of the protein without any cysteines
[13]. Their resolution was down to 0.97 Angstrom and the folding is more complex than anticipated
as predicted by the primary sequence. Glycosylation is another factor to consider for crystallization
and we have found 10 sites within HARE and there are likely more in Stabilin-2. Structurally
identifying individual domains may be misleading due to the number of unknown disulfide bonds
in a folded and functional receptor. The best candidate for crystallizing this protein for understanding
its overall structure is probably the soluble form of HARE expressed in either mammalian or insect
cell systems which will fold it with high fidelity. Understanding how Stabilin-2 interacts with its
ligands and functions with other proteins will require structural modeling going forward.
The hepatic and renal systems eliminate nearly all of the foreign molecules that are either
injected or consumed. Very small molecules tend to be eliminated through the kidney, whereas larger
molecules or more complex structures such as polymers or nanoparticles are cleared through the liver
[88,89]. Within the liver, injected pharmaceuticals or material absorbed from oral ingestion into the
circulatory system is cleared by receptor-mediated LSEC scavenging or by hepatobiliary elimination.
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Due to the prolific endocytic activity of LSECs and, to a lesser extent, other liver cells, pharmaceuticals
or their carriers may either target or avoid Stabilins or other scavenger receptors of the liver. Our
work using phosphorothioate-based antisense oligonucleotides (PS-ASOs), which are used to
downregulate gene expression or correct RNA splicing for human therapy, indicates that PS-ASOs
that are highly negatively charged and with a flexible structure (single stranded) will bind with the
Stabilins, whereas more neutral chemistries or double stranded ASOs will not [30,90]. Likewise,
ammonium-functionalized carbon nanotubes (fCNTs), which are anionic and considerably larger,
bind specifically with the Stabilins and are taken up by LSECs and not by Kupffer cells nor
hepatocytes [91]. Studies in the zebrafish model suggested that small anionic nanoparticles that are
50-250 nm in size tend to be taken up by the Stabilins [92]. This fits within the theoretical limit of
forming pinocytic vesicles which are, on average, 100–130 nm in diameter. Altering the shape of the
nanoparticle and the chemistry for overall charge will affect its affinity for the Stabilins, in particular,
Stabilin-2 [93]. With that in mind, the design of pharmaceuticals and their carriers need to be specific
for either targeting or avoiding the Stabilins for optimal efficacy.
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